Nearly two dozen possible COVID-19 vaccines are in various stages of testing around the world. Candidates from China and Britain's Oxford University also are entering final testing stages.

Moderna's promising COVID trial results lift Europe and U.S. futures.

The vaccine is set to start phase III trials, considered to be the biggest and the most crucial one in the testing phase, from July 27.

Nearly two dozen possible COVID-19 vaccines are in various stages of testing around the world. Candidates from China and Britain's Oxford University also are entering final testing stages.

COVID-19 vaccine: Moderna is set to begin its phase 3 clinical trial on a coronavirus vaccine. It's the first phase 3 trial in the U.S.

The promising vaccine, developed by Dr. Anthony Fauci’s colleagues at the National Institutes of Health and Moderna Inc., was the first tested in the U.S.

A Covid-19 vaccine developed by the biotechnology company Moderna in partnership with the National Institutes of Health has been found to induce immune responses in all of the volunteers who received it in a Phase 1 study.

People who got the shot had immune responses that could protect them from the coronavirus, and Moderna is preparing to test the shot in more people.

People who got the shot had immune responses that could protect them from the coronavirus, and Moderna is preparing to test the shot in more people.

New U.S.-funded trial could deliver answer by year-end

New U.S.-funded trial would seek 30,000 subjects and could deliver answer by year-end

Check out the companies making headlines after the bell.

The S&P 500 closed lower on Tuesday, as investors focused on a report questioning Moderna's recent coronavirus vaccine early-stage trial results, wiping out modest gains on the benchmark index in the last hour of trading.

These are the stocks posting the largest moves in midday trading.

Dr. Marc Siegel weighs in on a report that Moderna coronavirus vaccine trials are showing promising results and are now on an accelerated timeline

Noubar Afeyan says Moderna aims to make a billion doses of its promising COVID-19 vaccine candidate annually, by the end of 2021.

Without having reached phase two trials, Moderna's vaccine candidate still managed to spur buying from Wall Street to the ASX where miners led a 99-point rally.

Moderna Inc's experimental COVID-19 vaccine, the first to be tested in the United States, produced protective antibodies in a small group of healthy volunteers, according to very early data released by the biotech company on Monday.

“These data substantiate our belief that mRNA-1273 has the potential to prevent Covid-19 disease,” says Moderna's chief medical officer, Tal Zaks.

Check out the companies making headlines after the bell.

Promising vaccine trials, questionable research ethics, and clearly bad policy.

The former pharmaceutical executive tapped last week to head Operation Warp Speed will divest $10 million in a company considered a front-runner.